FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Luke O'Neill

Research Profile

Chemicals & Drugs

Physiology

Living Beings

Mouse

Anatomy

Co-author Network

Publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Luke O'Neill (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dympna J Connolly; Luke A J O'Neill; Anne F McGettrick
The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling.
The Journal of biological chemistry 2013;288(8):5616-23.
2013: Luke A J O'Neill
Immunology. Sensing the dark side of DNA.
Science (New York, N.Y.) 2013;339(6121):763-4.
2013: Luke A J O'Neill; D Grahame Hardie
Metabolism of inflammation limited by AMPK and pseudo-starvation.
Nature 2013;493(7432):346-55.
2012: Luke A J O'Neill
"Transflammation": when innate immunity meets induced pluripotency.
Cell 2012;151(3):471-3.
2012: Moritz Haneklaus; Mariola Kurowska-Stolarska; Motti Gerlic; Wolfgang Hammerschmidt; Iain B McInnes; Luke A J O'Neill; Dagmar Pich; Ashleigh-Ann Rainey; Seth L Masters
Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(8):3795-9.
2012: Jennifer K Dowling; Luke A J O'Neill
Biochemical regulation of the inflammasome.
Critical reviews in biochemistry and molecular biology 2012;47(5):424-43.
2012: Mihai G Netea; Cisca Wijmenga; Luke A J O'Neill
Genetic variation in Toll-like receptors and disease susceptibility.
Nature immunology 2012;13(6):535-42.
2012: Andrea Scharfe-Nugent; Susan B Carpenter; Sinéad C Corr; Sean Daly; Brendan Doyle; Katherine A Fitzgerald; Louise Keogh; Cara Martin; John J O'Leary; Luke A J O'Neill
TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia.
Journal of immunology (Baltimore, Md. : 1950) 2012;188(11):5706-12.
2012: Sarah L Doyle; Gwyneth Jane Farrar; Joe G Hollyfield; Marian Humphries; Paul F Kenna; Anna-Sophia Kiang; E C Lavelle; Andres Mori; Luke A J O'Neill; Ema Ozaki; Robert G Salomon; Matthew Campbell; Peter Humphries
NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components.
Nature medicine 2012;18(5):791-8.
2012: Haitao Wen; Jenny P-Y Ting; Luke A J O'Neill
A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation?
Nature immunology 2012;13(4):352-7.
2012: Fatih Arslan; Renate de Jong; Lars Akeroyd; Jaco H Houtgraaf; Kushan Kazemi; Brian Keogh; William J McCormack; Peter McGuirk; Luke A J O'Neill; Gerard Pasterkamp; Mary Reilly; Mirjam B Smeets; Leo Timmers; Dominique P V de Kleijn
Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.
Circulation. Cardiovascular interventions 2012;5(2):279-87.
2012: Camille Aubry; Sinéad C Corr; Thomas Decker; Olivier Dussurget; Céline Goulard; Amanda M Jamieson; Ruth Jones; Luke A J O'Neill; Sebastian Wienerroither; Pascale Cossart
Both TLR2 and TRIF contribute to interferon-β production during Listeria infection.
PloS one 2012;7(3):e33299.
2012: Sarah L Doyle; Terje Espevik; Harald Husebye; Dympna J Connolly; Luke A J O'Neill; Anne F McGettrick
The GOLD domain-containing protein TMED7 inhibits TLR4 signalling from the endosome upon LPS stimulation.
Nature communications 2012;3():707.
2011: Susan Carpenter; Aisling Dunne; Paulina Wochal; Luke A J O'Neill
Toll-like receptor 3 (TLR3) signaling requires TLR4 Interactor with leucine-rich REPeats (TRIL).
The Journal of biological chemistry 2011;286(44):38795-804.
2011: Luke A J O'Neill; Andrew G Bowie
The powerstroke and camshaft of the RIG-I antiviral RNA detection machine.
Cell 2011;147(2):259-61.
2011: Luke A J O'Neill
A critical role for citrate metabolism in LPS signalling.
The Biochemical journal 2011;438(3):e5-6.
2011: Elizabeth J Hennessy; David Santamaria; Frederick J Sheedy; Mariano Barbacid; Luke A J O'Neill
Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6.
The Journal of biological chemistry 2011;286(29):25531-9.
2011: Luke A J O'Neill
Plant science. Innate immunity in plants goes to the PUB.
Science (New York, N.Y.) 2011;332(6036):1386-7.
2011: Gillian M Tannahill; Luke A J O'Neill
The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3.
FEBS letters 2011;585(11):1568-72.
2011: Seth L Masters; Eicke Latz; Luke A J O'Neill
The inflammasome in atherosclerosis and type 2 diabetes.
Science translational medicine 2011;3(81):81ps17.
2011: Seth L Masters; Luke A J O'Neill
Disease-associated amyloid and misfolded protein aggregates activate the inflammasome.
Trends in molecular medicine 2011;17(5):276-82.
2011: Luke A J O'Neill; Frederick J Sheedy; Claire E McCoy
MicroRNAs: the fine-tuners of Toll-like receptor signalling.
Nature reviews. Immunology 2011;11(3):163-75.
2011: Nicholas J Gay; Monique Gangloff; Luke A J O'Neill
What the Myddosome structure tells us about the initiation of innate immunity.
Trends in immunology 2011;32(3):104-9.
2011: Luke A J O'Neill
Counter-regulation in the IKK family.
The Biochemical journal 2011;434(1):e1-2.
2011: Sinéad M Smith; Anthony P Moran; Shane P Duggan; Salah E Ahmed; Abdelhafeez S Mohamed; Henry J Windle; Luke A J O'Neill; Dermot P Kelleher
Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(4):2462-71.
2011: Luke A J O'Neill
Synergism between NOD-like receptors and Toll-like receptors in human B lymphocytes.
Journal of leukocyte biology 2011;89(2):173-5.
2010: Luke A J O'Neill
Outfoxing Foxo1 with miR-182.
Nature immunology 2010;11(11):983-4.
2010: Seth L Masters; Aisling Dunne; Shoba L Subramanian; Rebecca L Hull; Gillian M Tannahill; Fiona A Sharp; Christine Becker; luigi franchi; Eiji Yoshihara; Zhe Chen; Niamh Mullooly; Lisa A Mielke; James Harris; Rebecca C Coll; Kingston H G Mills; K Hun Mok; Philip Newsholme; Gabriel Nuñez; Junji Yodoi; Steven E Kahn; E C Lavelle; Luke A J O'Neill
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.
Nature immunology 2010;11(10):897-904.
2010: Theo S Plantinga; Omar J M Hamza; Janet A Willment; Bart Ferwerda; Nicole M D van de Geer; Paul E Verweij; M I N Matee; Kathy Banahan; Luke A J O'Neill; Bart Jan Kullberg; Gordon D Brown; Andre J A M van der Ven; Mihai G Netea
Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.
Journal of acquired immune deficiency syndromes (1999) 2010;55(1):87-94.
2010: Claire E McCoy; Frederick J Sheedy; Joseph E Qualls; Sarah L Doyle; Susan R Quinn; Peter J Murray; Luke A J O'Neill
IL-10 inhibits miR-155 induction by toll-like receptors.
The Journal of biological chemistry 2010;285(27):20492-8.
2010: Luke A J O'Neill
Stopping sepsis by targeting sphingosine kinase 1.
Science translational medicine 2010;2(36):36ps29.
2010: Aisling Dunne; Susan Carpenter; Constantinos Brikos; Pearl Gray; Astrid Strelow; Holger Wesche; Nick Morrice; Luke A J O'Neill
IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).
The Journal of biological chemistry 2010;285(24):18276-82.
2010: Luke A J O'Neill; Andrew G Bowie
Sensing and signaling in antiviral innate immunity.
Current biology : CB 2010;20(7):R328-33.
2010: Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Targeting Toll-like receptors: emerging therapeutics?
Nature reviews. Drug discovery 2010;9(4):293-307.
2010: Xiao Zhang; Freya Shephard; Hong B Kim; Ian R Palmer; Selina McHarg; Gregory J S Fowler; Luke A J O'Neill; Endre Kiss-Toth; Eva E Qwarnstrom
TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Ras-dependent amplification of NF-kappaB.
The Journal of biological chemistry 2010;285(10):7222-32.
2010: Anne F McGettrick; Luke A J O'Neill
Localisation and trafficking of Toll-like receptors: an important mode of regulation.
Current opinion in immunology 2010;22(1):20-7.
2010: Frederick J Sheedy; Eva Palsson-McDermott; Elizabeth J Hennessy; Cara Martin; John J O'Leary; Qingguo Ruan; Derek S Johnson; Youhai Chen; Luke A J O'Neill
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21.
Nature immunology 2010;11(2):141-7.
2010: Fatih Arslan; Mirjam B Smeets; Luke A J O'Neill; Brian Keogh; Peter McGuirk; Leo Timmers; Claudia Tersteeg; Imo E Hoefer; Pieter A Doevendans; Gerard Pasterkamp; Dominique P V de Kleijn
Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody.
Circulation 2010;121(1):80-90.
2010: Anne F McGettrick; Luke A J O'Neill
Regulators of TLR4 signaling by endotoxins.
Sub-cellular biochemistry 2010;53():153-71.
2010: Rebecca C Coll; Luke A J O'Neill
New insights into the regulation of signalling by toll-like receptors and nod-like receptors.
Journal of innate immunity 2010;2(5):406-21.
2009: Luke A J O'Neill
Boosting the brain's ability to block inflammation via microRNA-132.
Immunity 2009;31(6):854-5.
2009: Christine E Becker; Emma M Creagh; Luke A J O'Neill
Rab39a binds caspase-1 and is required for caspase-1-dependent interleukin-1beta secretion.
The Journal of biological chemistry 2009;284(50):34531-7.
2009: Luke A J O'Neill
A feed-forward loop involving hyaluronic acid and toll-like receptor-4 as a treatment for colitis?
Gastroenterology 2009;137(6):1889-91.
2009: Elaine F Kenny; Suzanne Talbot; Mei Gong; Douglas T Golenbock; Clare E Bryant; Luke A J O'Neill
MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(6):3642-51.
2009: Susan Carpenter; Thaddeus Carlson; Jérôme Dellacasagrande; Amaya Garcia; Sharon Gibbons; Paul Hertzog; Anthony Lyons; Lih-Ling Lin; Marina Lynch; Tom Monie; Caroline Murphy; Katherine J Seidl; Christine Wells; Aisling Dunne; Luke A J O'Neill
TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(6):3989-95.
2009: Susan Carpenter; Luke A J O'Neill
Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins.
The Biochemical journal 2009;422(1):1-10.
2009: Luke A J O'Neill
DNA makes RNA makes innate immunity.
Cell 2009;138(3):428-30.
2009: Luke A J O'Neill; Clare E Bryant; Sarah L Doyle
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
Pharmacological reviews 2009;61(2):177-97.
2009: Eva M Palsson-McDermott; Sarah L Doyle; Anne F McGettrick; Matthew Hardy; Harald Husebye; Kathy Banahan; Mei Gong; Douglas T Golenbock; Terje Espevik; Luke A J O'Neill
TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway.
Nature immunology 2009;10(6):579-86.
2009: Sinead C Corr; Luke A J O'Neill
Listeria monocytogenes infection in the face of innate immunity.
Cellular microbiology 2009;11(5):703-9.
2009: Luke A J O'Neill
Regulation of signaling by non-degradative ubiquitination.
The Journal of biological chemistry 2009;284(13):8209.
2009: Fiona A Sharp; Darren Ruane; Benjamin Claass; Emma M Creagh; James Harris; Padma Malyala; Manomohan Singh; Derek T O'Hagan; Virginie Pétrilli; Jurg Tschopp; Luke A J O'Neill; E C Lavelle
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(3):870-5.
2009: Sinead C Corr; Luke A J O'Neill
Genetic variation in Toll-like receptor signalling and the risk of inflammatory and immune diseases.
Journal of innate immunity 2009;1(4):350-7.
2009: Claire E McCoy; Luke A J O'Neill
Toll-like receptors: methods and protocols.Preface.
Methods in molecular biology (Clifton, N.J.) 2009;517():v-vi.
2008: Luke A J O'Neill
The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.
Immunological reviews 2008;226():10-8.
2008: Elaine F Kenny; Luke A J O'Neill
Signalling adaptors used by Toll-like receptors: an update.
Cytokine 2008;43(3):342-9.
2008: Luke A J O'Neill
When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction.
Immunity 2008;29(1):12-20.
2008: Luke A J O'Neill
Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
Nature clinical practice. Rheumatology 2008;4(6):319-27.
2008: Ceire Costelloe; Melanie Watson; Aine Murphy; Keith McQuillan; Christine Loscher; Michelle E Armstrong; Cecilia Garlanda; Alberto Mantovani; Luke A J O'Neill; Kingston H G Mills; Marina A Lynch
IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8.
Journal of neurochemistry 2008;105(5):1960-9.
2008: Claire E McCoy; Susan Carpenter; Eva M Pålsson-McDermott; Linden J Gearing; Luke A J O'Neill
Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation.
The Journal of biological chemistry 2008;283(21):14277-85.
2008: Luke A J O'Neill
Immunology. How frustration leads to inflammation.
Science (New York, N.Y.) 2008;320(5876):619-20.
2008: Luke A J O'Neill
'Fine tuning' TLR signaling.
Nature immunology 2008;9(5):459-61.
2008: Luke A J O'Neill
Innate immunity: squelching anti-viral signalling with NLRX1.
Current biology : CB 2008;18(7):R302-4.
2008: Luke A J O'Neill
Bacteria fight back against Toll-like receptors.
Nature medicine 2008;14(4):370-2.
2008: Constantinos Brikos; Luke A J O'Neill
Signalling of toll-like receptors.
Handbook of experimental pharmacology 2008;(183):21-50.
2008: Claire E McCoy; Luke A J O'Neill
The role of toll-like receptors in macrophages.
Frontiers in bioscience : a journal and virtual library 2008;13():62-70.
2007: Sarah L Doyle; Caroline Jefferies; Conleth Feighery; Luke A J O'Neill
Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.
The Journal of biological chemistry 2007;282(51):36953-60.
2007: Luke A J O'Neill
TAMpering with toll-like receptor signaling.
Cell 2007;131(6):1039-41.
2007: Eva M Pålsson-McDermott; Luke A J O'Neill
Building an immune system from nine domains.
Biochemical Society transactions 2007;35(Pt 6):1437-44.
2007: Eva M Pålsson-McDermott; Luke A J O'Neill
The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases.
Irish journal of medical science 2007;176(4):253-60.
2007: Anne F McGettrick; Luke A J O'Neill
Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis.
British journal of haematology 2007;139(2):185-93.
2007: Christine E Becker; Luke A J O'Neill
Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs.
Seminars in immunopathology 2007;29(3):239-48.
2007: Constantinos Brikos; Robin Wait; Shajna Begum; Luke A J O'Neill; Jeremy Saklatvala
Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components.
Molecular & cellular proteomics : MCP 2007;6(9):1551-9.
2007: Tanya M Watters; Elaine F Kenny; Luke A J O'Neill
Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins.
Immunology and cell biology 2007;85(6):411-9.
2007: Susan Carpenter; Luke A J O'Neill
How important are Toll-like receptors for antimicrobial responses?
Cellular microbiology 2007;9(8):1891-901.
2007: Frederick J Sheedy; Luke A J O'Neill
The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling.
Journal of leukocyte biology 2007;82(2):196-203.
2007: Claudia Wietek; Luke A J O'Neill
Diversity and regulation in the NF-kappaB system.
Trends in biochemical sciences 2007;32(7):311-9.
2007: Caroline Gubser; Rory Goodbody; Andrea Ecker; Gareth Brady; Luke A J O'Neill; Nathalie Jacobs; Geoffrey L Smith
Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence.
The Journal of general virology 2007;88(Pt 6):1667-76.
2007: Luke A J O'Neill; Andrew G Bowie
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.
Nature reviews. Immunology 2007;7(5):353-64.
2007: Sinead M Miggin; Eva M Pålsson-McDermott; Aisling Dunne; Caroline Jefferies; Emmanuel Pinteaux; Kathy Banahan; Caroline Murphy; Paul N Moynagh; Masahiro Yamamoto; Shizuo Akira; Nancy J Rothwell; Douglas T Golenbock; Katherine A Fitzgerald; Luke A J O'Neill
NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(9):3372-7.
2007: Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Resolution of inflammation: state of the art, definitions and terms.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(2):325-32.
2007: Ricardo Núñez Miguel; Joyce Wong; Julian F Westoll; Heather J Brooks; Luke A J O'Neill; nicholas gay; Clare E Bryant; Tom P Monie
A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins.
PloS one 2007;2(8):e788.
2006: Claudia Wietek; Catherine S Cleaver; Valerie Ludbrook; Jonathan Wilde; Julia White; David J Bell; Michael Lee; Marion Dickson; Keith Ray; Luke A J O'Neill
IkappaB kinase epsilon interacts with p52 and promotes transactivation via p65.
The Journal of biological chemistry 2006;281(46):34973-81.
2006: Sarah L Doyle; Luke A J O'Neill
Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity.
Biochemical pharmacology 2006;72(9):1102-13.
2006: Luke A J O'Neill
DisSARMing Toll-like receptor signaling.
Nature immunology 2006;7(10):1023-5.
2006: Emma M Creagh; Luke A J O'Neill
TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity.
Trends in immunology 2006;27(8):352-7.
2006: Sinead M Miggin; Luke A J O'Neill
New insights into the regulation of TLR signaling.
Journal of leukocyte biology 2006;80(2):220-6.
2006: Luke A J O'Neill
Targeting signal transduction as a strategy to treat inflammatory diseases.
Nature reviews. Drug discovery 2006;5(7):549-63.
2006: Anne F McGettrick; Elizabeth K Brint; Eva M Palsson-McDermott; Daniel Rowe; Douglas T Golenbock; nicholas gay; Katherine A Fitzgerald; Luke A J O'Neill
Trif-related adapter molecule is phosphorylated by PKC{epsilon} during Toll-like receptor 4 signaling.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(24):9196-201.
2006: Daniel Rowe; Anne F McGettrick; Eicke Latz; Brian G Monks; nicholas gay; Masahiro Yamamoto; Shizuo Akira; Luke A J O'Neill; Katherine A Fitzgerald; Douglas T Golenbock
The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(16):6299-304.
2006: Pearl Gray; Aisling Dunne; Constantinos Brikos; Caroline Jefferies; Sarah L Doyle; Luke A J O'Neill
MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction.
The Journal of biological chemistry 2006;281(15):10489-95.
2006: Ashley Mansell; Rosealee Smith; Sarah L Doyle; Pearl Gray; Jennifer E Fenner; Peter J Crack; Sandra E Nicholson; Douglas J Hilton; Luke A J O'Neill; Paul J Hertzog
Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation.
Nature immunology 2006;7(2):148-55.
2006: Luke A J O'Neill
How Toll-like receptors signal: what we know and what we don't know.
Current opinion in immunology 2006;18(1):3-9.
2005: Luke A J O'Neill
TLRs play good cop, bad cop in the lung.
Nature medicine 2005;11(11):1161-2.
2005: Dermot O'Toole; Mohamed M M Abdel-Latif; Aideen Long; Henry J Windle; Anne M Murphy; Andrew Bowie; Luke A J O'Neill; Donald G Weir; Dermot Kelleher
Low pH and Helicobacter pylori increase nuclear factor kappa B binding in gastric epithelial cells: a common pathway for epithelial cell injury?
Journal of cellular biochemistry 2005;96(3):589-98.
2005: Gareth Brady; Louise Boggan; Andrew G Bowie; Luke A J O'Neill
Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1.
The Journal of biological chemistry 2005;280(35):30723-34.
2005: Sarah L Doyle; Caroline Jefferies; Luke A J O'Neill
Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide.
The Journal of biological chemistry 2005;280(25):23496-501.
2005: Aisling Dunne; Luke A J O'Neill
Adaptor usage and Toll-like receptor signaling specificity.
FEBS letters 2005;579(15):3330-5.
2005: Foo Y Liew; Damo Xu; Elizabeth K Brint; Luke A J O'Neill
Negative regulation of toll-like receptor-mediated immune responses.
Nature reviews. Immunology 2005;5(6):446-58.
2005: Luke A J O'Neill
Immunity's early-warning system.
Scientific American 2005;292(1):24-31.
2004: Luke A J O'Neill
TLRs: Professor Mechnikov, sit on your hat.
Trends in immunology 2004;25(12):687-93.
2004: Endre Kiss-Toth; Stephanie M Bagstaff; Hye-Youn Sung; Veronika Jozsa; Clare E Dempsey; Jim C Caunt; Kevin M Oxley; David H Wyllie; Timea Polgar; Mary Harte; Luke A J O'Neill; Eva E Qwarnstrom; Steven K Dower
Human tribbles, a protein family controlling mitogen-activated protein kinase cascades.
The Journal of biological chemistry 2004;279(41):42703-8.
2004: Eva M Pålsson-McDermott; Luke A J O'Neill
Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.
Immunology 2004;113(2):153-62.
2004: Ashley Mansell; Elizabeth K Brint; Jodee A Gould; Luke A J O'Neill; Paul J Hertzog
Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4.
The Journal of biological chemistry 2004;279(36):37227-30.
2004: Luke A J O'Neill
How NOD-ing off leads to Crohn disease.
Nature immunology 2004;5(8):776-8.
2004: Javed A Khan; Elizabeth K Brint; Luke A J O'Neill; Liang Tong
Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL.
The Journal of biological chemistry 2004;279(30):31664-70.
2004: Anne F McGettrick; Luke A J O'Neill
The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction.
Molecular immunology 2004;41(6-7):577-82.
2004: Matthew P Hardy; Luke A J O'Neill
The murine IRAK2 gene encodes four alternatively spliced isoforms, two of which are inhibitory.
The Journal of biological chemistry 2004;279(26):27699-708.
2004: Matthew P Hardy; Anne F McGGettrick; Luke A J O'Neill
Transcriptional regulation of the human TRIF (TIR domain-containing adaptor protein inducing interferon beta) gene.
The Biochemical journal 2004;380(Pt 1):83-93.
2004: Elizabeth K Brint; Damo Xu; Haiying Liu; Aisling Dunne; Andrew N J McKenzie; Luke A J O'Neill; Foo Y Liew
ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance.
Nature immunology 2004;5(4):373-9.
2004: Caroline Jefferies; Luke A J O'Neill
Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling?
Immunology letters 2004;92(1-2):15-22.
2004: Luke A J O'Neill
Immunology. After the toll rush.
Science (New York, N.Y.) 2004;303(5663):1481-2.
2003: Claudia Wietek; Sinead M Miggin; Caroline Jefferies; Luke A J O'Neill
Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa.
The Journal of biological chemistry 2003;278(51):50923-31.
2003: Aisling Dunne; Mikael Ejdebäck; Phumzile L Ludidi; Luke A J O'Neill; nicholas gay
Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88.
The Journal of biological chemistry 2003;278(42):41443-51.
2003: Paul J Hertzog; Luke A J O'Neill; John A Hamilton
The interferon in TLR signaling: more than just antiviral.
Trends in immunology 2003;24(10):534-9.
2003: Eleanor F Dunn; nicholas gay; Adrian F Bristow; David P Gearing; Luke A J O'Neill; Xue Yuan Pei
High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity.
Biochemistry 2003;42(37):10938-44.
2003: Luke A J O'Neill
SIGIRR puts the brakes on Toll-like receptors.
Nature immunology 2003;4(9):823-4.
2003: Luke A J O'Neill
Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases.
Current opinion in pharmacology 2003;3(4):396-403.
2003: Stephen G Ward; Luke A J O'Neill
Spotlight on new anti-inflammatory drug targets in the immune system.
Current opinion in pharmacology 2003;3(4):391-5.
2003: Caroline Jefferies; Sarah Doyle; Cornelia Brunner; Aisling Dunne; Elizabeth K Brint; Claudia Wietek; Eva Walch; Thomas Wirth; Luke A J O'Neill
Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.
The Journal of biological chemistry 2003;278(28):26258-64.
2003: Luke A J O'Neill; Katherine A Fitzgerald; Andrew G Bowie
The Toll-IL-1 receptor adaptor family grows to five members.
Trends in immunology 2003;24(6):286-90.
2003: Luke A J O'Neill
The role of MyD88-like adapters in Toll-like receptor signal transduction.
Biochemical Society transactions 2003;31(Pt 3):643-7.
2003: Luke A J O'Neill; Zarin Brown; Stephen G Ward
Toll-like receptors in the spotlight.
Nature immunology 2003;4(4):299.
2003: Aisling Dunne; Luke A J O'Neill
The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense.
Science's STKE : signal transduction knowledge environment 2003;2003(171):re3.
2003: Mary T Harte; Ismar R Haga; Geraldine Maloney; Pearl Gray; Patrick Reading; Nathan W Bartlett; Geoffrey L Smith; Andrew G Bowie; Luke A J O'Neill
The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense.
The Journal of experimental medicine 2003;197(3):343-51.
2003: Luke A J O'Neill; Aisling Dunne; Mikael Ejdebäck; Pearl Gray; Caroline Jefferies; Claudia Wietek
Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.
Journal of endotoxin research 2003;9(1):55-9.
2002: Elizabeth K Brint; Katherine A Fitzgerald; Philip Smith; Anthony J Coyle; Jose-Carlos Gutierrez-Ramos; Padraic G Fallon; Luke A J O'Neill
Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction.
The Journal of biological chemistry 2002;277(51):49205-11.
2002: Luke A J O'Neill
Wanted: a molecular basis for specificity in toll-like receptor signal transduction.
Molecular cell 2002;10(5):969-71.
2002: Valerie M Corrigall; Luke A J O'Neill
Using immunotherapy to treat rheumatic diseases.
Trends in immunology 2002;23(8):383-4.
2002: Claudia Wietek; Luke A J O'Neill
IRAK-4: a new drug target in inflammation, sepsis, and autoimmunity.
Molecular interventions 2002;2(4):212-5.
2002: Luke A J O'Neill
Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal?
Trends in immunology 2002;23(6):296-300.
2002: Eva Pålsson McDermott; Luke A J O'Neill
Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1.
The Journal of biological chemistry 2002;277(10):7808-15.
2002: Luke A J O'Neill
Is there a novel brain interleukin 1 receptor that signals ischaemic brain damage?
Trends in pharmacological sciences 2002;23(3):109-10.
2002: Luke A J O'Neill
Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily.
Current topics in microbiology and immunology 2002;270():47-61.
2001: A Mansell; A Reinicke; D M Worrall; Luke A J O'Neill
The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4.
FEBS letters 2001;508(3):313-7.
2001: A Mansell; N Khelef; P Cossart; Luke A J O'Neill
Internalin B activates nuclear factor-kappa B via Ras, phosphoinositide 3-kinase, and Akt.
The Journal of biological chemistry 2001;276(47):43597-603.
2001: Katherine A Fitzgerald; E M Palsson-McDermott; Andrew G Bowie; Caroline Jefferies; Ashley Mansell; G Brady; Elizabeth K Brint; Aisling Dunne; Pearl Gray; M T Harte; D McMurray; Dirk E Smith; John E Sims; Timothy A Bird; Luke A J O'Neill
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.
Nature 2001;413(6851):78-83.
2001: Caroline Jefferies; Andrew G Bowie; G Brady; E L Cooke; X Li; Luke A J O'Neill
Transactivation by the p65 subunit of NF-kappaB in response to interleukin-1 (IL-1) involves MyD88, IL-1 receptor-associated kinase 1, TRAF-6, and Rac1.
Molecular and cellular biology 2001;21(14):4544-52.
2000: Andrew G Bowie; Luke A J O'Neill
Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(12):7180-8.
2000: A Bowie; Endre Kiss-Toth; J A Symons; G L Smith; Steven K Dower; Luke A J O'Neill
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(18):10162-7.
2000: M P Boland; Katherine A Fitzgerald; Luke A J O'Neill
Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
The Journal of biological chemistry 2000;275(33):25231-8.
2000: Luke A J O'Neill
The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense.
Science's STKE : signal transduction knowledge environment 2000;2000(44):re1.
2000: Katherine A Fitzgerald; Luke A J O'Neill
The role of the interleukin-1/Toll-like receptor superfamily in inflammation and host defence.
Microbes and infection / Institut Pasteur 2000;2(8):933-43.
2000: Luke A J O'Neill; C A Dinarello
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense.
Immunology today 2000;21(5):206-9.
2000: A Mansell; L Braun; P Cossart; Luke A J O'Neill
A novel function of InIB from Listeria monocytogenes: activation of NF-kappaB in J774 macrophages.
Cellular microbiology 2000;2(2):127-36.
2000: Katherine A Fitzgerald; Andrew G Bowie; B S Skeffington; Luke A J O'Neill
Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(4):2053-63.
2000: Caroline Jefferies; Luke A J O'Neill
Rac1 regulates interleukin 1-induced nuclear factor kappaB activation in an inhibitory protein kappaBalpha-independent manner by enhancing the ability of the p65 subunit to transactivate gene expression.
The Journal of biological chemistry 2000;275(5):3114-20.
2000: Andrew G Bowie; Luke A J O'Neill
Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries.
Biochemical pharmacology 2000;59(1):13-23.
1999: JS Matthews; Luke A J O'Neill
Distinct roles for p42/p44 and p38 mitogen-activated protein kinases in the induction of IL-2 by IL-1.
Cytokine 1999;11(9):643-55.
1998: M P Boland; Luke A J O'Neill
Ceramide activates NFkappaB by inducing the processing of p105.
The Journal of biological chemistry 1998;273(25):15494-500.
1998: Paul Brennan; Luke A J O'Neill
Inhibition of nuclear factor kappaB by direct modification in whole cells--mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers.
Biochemical pharmacology 1998;55(7):965-73.
1997: Luke A J O'Neill; JS Matthews; E Pålsson; C Jeffries; Paul Brennan; D A Cantrell
Interleukin 1 signalling: synergy with Rac1 and Pi3 kinase.
Biochemical Society transactions 1997;25(4):S578.
1997: Andrew G Bowie; Paul N Moynagh; Luke A J O'Neill
Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells.
The Journal of biological chemistry 1997;272(41):25941-50.
1997: T M Mahon; JS Matthews; Luke A J O'Neill
Staurosporine, but not Ro 31-8220, induces interleukin 2 production and synergizes with interleukin 1alpha in EL4 thymoma cells.
The Biochemical journal 1997;325 ( Pt 1)():39-45.
1997: M P Boland; S J Foster; Luke A J O'Neill
Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells.
The Journal of biological chemistry 1997;272(20):12952-60.
1997: A Bowie; Luke A J O'Neill
Vitamin C inhibits NF kappa B activation in endothelial cells.
Biochemical Society transactions 1997;25(1):131S.
1997: A Bowie; Luke A J O'Neill
Studies into the mechanism of NF kappa B activation by IL1, TNF and H2O2 in primary and transformed endothelial cells.
Biochemical Society transactions 1997;25(1):125S.
1997: Luke A J O'Neill
Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture.
Biochemical Society transactions 1997;25(1):295-302.
1996: Paul Brennan; Luke A J O'Neill
2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC.
The Biochemical journal 1996;320 ( Pt 3)():975-81.
1996: dara dunican; R Griffiths; D C Williams; Luke A J O'Neill
Endothelin-1 increases arachidonic acid release in C6 glioma cells through a potassium-modulated influx of calcium.
Journal of neurochemistry 1996;67(2):830-7.
1996: T M Mahon; Luke A J O'Neill
Investigation into the role of protein kinase C in IL1 and PMA signalling in EL4.NOB-1 thymoma cells.
Biochemical Society transactions 1996;24(1):81S.
1996: Paul Brennan; Luke A J O'Neill
Inhibition of NF kappa B activity by oxidative processes in intact cells mechanism of action of pyrolidine dithiocarbamate and diamide.
Biochemical Society transactions 1996;24(1):3S.
1996: Luke A J O'Neill
Interleukin I receptors and signal transduction.
Biochemical Society transactions 1996;24(1):207-11.
1996: A Bowie; P N Moynagh; Luke A J O'Neill
Mechanism of NF kappa B activation by interleukin-1 and tumour necrosis factor in endothelial cells.
Biochemical Society transactions 1996;24(1):2S.
1996: M P Boland; S J Foster; Luke A J O'Neill
Activation of NF kappa B and potentiation of TNF-induced NF kappa B activation by ceramide analogues in leukemic cell lines despite the absence of an observed sphingomyelinase signalling event.
Biochemical Society transactions 1996;24(1):1S.
1995: T M Mahon; Luke A J O'Neill
Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit.
The Journal of biological chemistry 1995;270(48):28557-64.
1995: dara dunican; R Griffiths; Luke A J O'Neill; D C Williams
Depolarising levels of KCl inhibit endothelin-1-mediated release of arachidonic acid in rat C6 glioma cells.
Biochemical Society transactions 1995;23(2):285S.
1995: Luke A J O'Neill
Towards an understanding of the signal transduction pathways for interleukin 1.
Biochimica et biophysica acta 1995;1266(1):31-44.
1995: A Bowie; P N Moynagh; Luke A J O'Neill
The human endothelial cell line ECY304 as a model of endothelial cell activation by interleukin-1.
Biochemical Society transactions 1995;23(1):109S.
1995: T M Mahon; Luke A J O'Neill
Evidence for direct modification of NF kappa B by the tyrosine kinase inhibitor, herbimycin A.
Biochemical Society transactions 1995;23(1):111S.
1995: Paul Brennan; Luke A J O'Neill
Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals.
Biochimica et biophysica acta 1995;1260(2):167-75.
1994: P N Moynagh; D C Williams; Luke A J O'Neill
Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 expression in human glial cells by IL-1. Modulation by antioxidants.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(6):2681-90.
1993: Paul Brennan; A Bowie; Luke A J O'Neill
The effects of thiol modifiers on the activation of NF kappa B by interleukin-1.
Biochemical Society transactions 1993;21(4):390S.
1993: T M Mahon; Paul Brennan; Luke A J O'Neill
Evidence for a redox-sensitive protein tyrosine kinase in nuclear factor kappa B activation and interleukin 2 production in EL4.NOB1 cells.
Biochemical Society transactions 1993;21(4):389S.
1993: P N Moynagh; Luke A J O'Neill; D C Williams
Interleukin-1 and phorbol myristate acetate modulate the peripheral-type benzodiazepine receptor in lymphocytes and glial cells.
Biochemical pharmacology 1993;46(5):821-7.
1993: P N Moynagh; D C Williams; Luke A J O'Neill
Interleukin-1 activates transcription factor NF kappa B in glial cells.
The Biochemical journal 1993;294 ( Pt 2)():343-7.
1992: Luke A J O'Neill
How does interleukin-1 activate cells?
Kidney international 1992;41(3):546-9.